Frequently Asked Questions (FAQs)

The Ontario Cancer Research Ethics Board (OCREB) is an independent ethics committee responsible for reviewing and overseeing the conduct of cancer research clinical studies involving human participants in Ontario.

OCREB’s mandate is to review multi-site oncology clinical trials . For the purposes of its current mandate, “multi-centre” is defined as more than one participating Ontario centre using OCREB as the REB of Record, and “clinical trial” is defined as any research that prospectively assigns human participants to one or more health-related interventions to evaluate the effects on health outcomes.

Researchers, institutions, and research teams conducting cancer-related studies involving human participants in Ontario.

Proposals must be submitted online through the CTO Stream portal.

  • Full Board meetings are held on the second Friday of each month.
  • The submission deadline for new studies, amendments and continuing review applications is noon the 4th Tuesday of each month.
  • It’s recommended to submit initial applications as early as possible.
  • For deadlines and more details, see Meeting Schedule.
  • OCREB applications are submitted via the CTO Streamlined Ethics review process.
  • CTO Manuals and Guides for Applicants are also available here.
  • Applicants must have a CTO account in order to create a submission.
  • For OCREB studies, Consent templates must follow OCREB’s templates.
  • For guidance on how to complete application forms for OCREB, annotated forms are also on the OCREB website in the Applicants section.
  • For technical support with CTO Streamline issues, please contact the CTO Helpdesk: https://support.ctontario.ca/

Your application should include:

  • The most current version of the Protocol
  • Consent Forms
  • Scientific Review Letters (if applicable)
  • Signature Pages (if applicable, including Tx Beyond Progression/Re-start/Re-Challenge/Cross-Over)
  • Recruitment Materials (if applicable)
  • Participant-facing materials (e.g., Wallet Card, Study Brochures, Drug Diaries)
  • Questionnaires (if applicable, paper or electronic)
  • Investigator Brochure(s) for investigational products
  • Demographics Page CRF
  • Study Budget
  • Safety Board Charter (if applicable)
  • Translated Materials (if applicable, including certificates of translation)

The timeline varies depending on the complexity of the study, typically ranging from a few weeks to a couple of months. Applicants can expect a letter of modification within 5 business days after a Full Board meeting. If additional time is needed, this will be communicated promptly.

OCREB adheres to national and international standards, including the Tri-Council Policy Statement (TCPS2), as well as relevant provincial and federal regulations.

You will receive updates via email or through the online portal regarding review decisions and any required revisions.

Contact details, including email and phone support, are available on the OCREB website at Contact. 

Scroll to Top